Results 71 to 80 of about 11,407 (210)

In vivo Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Klebsiella pneumoniae Isolate With KPC-33 Carbapenemase

open access: yesFrontiers in Microbiology, 2021
We describe in vivo evolution of carbapenem and ceftazidime-avibactam resistance by analyzing four longitudinal Klebsiella pneumoniae clinical isolates from a patient with pneumonia following antimicrobial treatment.
Chunlei Wang   +33 more
doaj   +1 more source

Genomic Insights Into Carbapenem‐Resistant Klebsiella pneumoniae in Pediatric Bloodstream Infections in Zhejiang, China (2019–2024)

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
The primary mechanism of carbapenem resistance identified in pediatric CRKP‐BSI strains was the production of Class B metalloenzymes. We report, for the first time, an outbreak of bloodstream infections in a neonatal ward caused by the dissemination of NDM‐1‐producing ST25 K. pneumoniae.
Mingming Zhou   +8 more
wiley   +1 more source

Ceftazidime-avibactam/aztreonam combination synergy against carbapenem-resistant Gram-negative isolates: In vitro study

open access: yesCurrent Medicine Research and Practice
Background: The ceftazidime-avibactam combination is able to inhibit ESBLs, AmpCs and Class A carbapenemases and has been recommended for the treatment of complicated UTIs and ventilator-associated bacterial pneumonia.
Reena Rajan   +2 more
doaj   +1 more source

Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina

open access: yesMicrobiology Spectrum, 2022
We describe an outbreak of Klebsiella pneumoniae sequence type 11 (ST11) producing KPC variants resistant to ceftazidime-avibactam. Six patients hospitalized in the intensive care unit (mostly due to critical COVID pneumonia) presented infection or ...
Federico Nicola   +9 more
doaj   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

open access: yesWorld Journal of Surgery, EarlyView.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock   +41 more
wiley   +1 more source

Structural and Functional Aspects of Class A Carbapenemases. [PDF]

open access: yes, 2016
The fight against infectious diseases is probably one of the greatest public health challenges faced by our society, especially with the emergence of carbapenem-resistant gram-negatives that are in some cases pan-drug resistant.
Dortet, L, Iorga, BI, Naas, T
core   +3 more sources

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

open access: yesTransplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti   +6 more
wiley   +1 more source

Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]

open access: yes, 2015
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti   +142 more
core   +2 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

open access: yesAntibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin   +6 more
doaj   +1 more source

Emergence and Genomic Characterization of a Hypervirulent Klebsiella pneumoniae Isolate From a New Clone in Brazil

open access: yesMicrobiology and Immunology, Volume 70, Issue 5, Page 261-267, May 2026.
ABSTRACT Hypervirulent Klebsiella pneumoniae (hvKp) has emerged globally as a major public health concern, often associated with severe community‐acquired and healthcare‐associated human infections. Despite alerts from PAHO/WHO on convergent hvKp strains with multidrug resistance in Latin America, comprehensive data from Brazil, the region's largest ...
Carlos Henrique Camargo   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy